Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec"

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is one of the stocks Jim Cramer answered questions about recently. A caller asked Cramer for his opinion on the stock, and noted that it was rated a moderate buy by analysts and outperformed the S&P 500 by 60%. He replied:

“Okay, here’s the way we’re going to approach this: This is a pure spec, okay? I mean, total spec, $300 million company… I say you own it, but count it as part of your speculative part of your portfolio, and no more than that.”

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a biotechnology company developing gene therapies using its proprietary vector platform, with programs targeting retinal diseases, cystic fibrosis, geographic atrophy, alpha-1 antitrypsin deficiency, and Fabry disease. At the end of July, the company reported strong interim results from its Phase 2a SPECTRA trial of 4D-150 in diabetic macular edema, showing durable vision gains, improved retinal thickness, and a major reduction in supplemental injections compared to standard aflibercept treatment, with no cases of inflammation or serious safety concerns through 60 weeks.

While we acknowledge the potential of FDMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.